Compare AES Corp (AES) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AES Corp vs Bristol-Myers Squibb Co — how do they compare? AES Corp trades at $14.72 (market cap $10.49B), while Bristol-Myers Squibb Co trades at $63.02 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 12.4× AES Corp's market cap, and AES Corp pays the higher dividend (4.79%). Which is the better fit depends on your goals.
| AES | BMY | |
|---|---|---|
Market Cap | $10.49B | $129.94B |
Sector | Utilities | Health |
52-Week High | $17.28 | $65.89 |
52-Week Low | $12.51 | $42.60 |
Enterprise Value | $40.75B | $163.92B |
Dividend Yield | 4.79% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AES trades at $14.73, unchanged on the day, with a bullish technical signal from moving averages and a pending acquisition by Global Infrastructure Partners and EQT at $15 per share. The company reported revenue of $12.23B in 2025, with a net income margin of 7.43%, and has beaten earnings estimates in two of the last three quarters. Valuation ratios appear attractive with a P/E of 5.51 and P/S of 0.81, while cash flow from operations improved to $4.31B in 2025.
The outlook is dominated by the acquisition, offering a capped upside to $15. Strong profitability metrics like a 45.05% ROE and a 4.8% dividend yield provide support, but risks include shareholder litigation and regulatory scrutiny over the deal. Analyst sentiment is mixed with 42.86% buy ratings, reflecting uncertainty until transaction closure.
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AES Corp
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
